Recent Developments in Tuberculosis Diagnosis, Treatment, and Control Strategies: A Global Overview

DR UZAIR VOHRA[1], DR DARPAN AGRWAL[2], DR SHREY CHAUDHARI[3], DR HUMA KHAN[4]
[1, 2, 3]*Department of Pharmacy Practice, Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, India*

Abstract - Tuberculosis (TB) remains a significant global health challenge, particularly in resource-limited settings, where it disproportionately affects vulnerable populations. This review explores recent advancements in TB diagnosis and treatment, focusing on innovative strategies for both drug-sensitive and drug-resistant forms. A systematic search of relevant literature was conducted using databases such as PubMed, Scopus, and Web of Science, selecting studies published from 2015 to 2023 that report on TB diagnostic and treatment advancements. Advances in molecular diagnostics, such as the GeneXpert MTB/RIF, have revolutionized TB detection, enabling rapid and accurate identification of the disease and its drug-resistant strains. In terms of treatment, shorter and more effective drug regimens have emerged, enhancing adherence and improving patient outcomes. Notable developments include bedaquiline and delamanid for multidrug-resistant TB (MDR-TB), alongside the novel BPaL regimen, which combines pretomanid, bedaquiline, and linezolid, demonstrating high cure rates. Public health strategies, including active case finding and community-based treatment, are critical for curtailing transmission and addressing social determinants of health. This review also discusses ongoing research into vaccines, which are essential for preventing TB, particularly in high-risk populations. Despite the progress made, challenges remain in ensuring access to newer treatments in low-resource settings and addressing the rise of drug-resistant strains. This review provides a comprehensive overview of the current landscape in TB management and control, emphasizing improved treatment options and collaborative efforts necessary for enhanced patient outcomes and global TB eradication.

Indexed Terms- Tuberculosis, Diagnosis, Treatment, Drug Resistance, Public Health Strategies

I. INTRODUCTION

Tuberculosis is an airborne infectious disease caused by Mycobacterium tuberculosis. Despite significant advancements in medical research, TB remains a leading cause of mortality, particularly in developing nations. The World Health Organization (WHO) reports that TB accounted for over 1.4 million deaths globally in 2022 (1). The rising incidence of multidrug-resistant TB (MDR-TB) complicates global control efforts, creating an urgent need for novel approaches in diagnosis, treatment, and prevention (2). This review explores the latest developments in TB management, focusing on the most effective treatment options for both drug-sensitive and drug-resistant TB.

Global Epidemiology of Tuberculosis The global distribution of TB continues to reflect socioeconomic disparities, with the highest burden observed in low- and middle-income countries. WHO's Global Tuberculosis Report 2022 indicates that while TB incidence is declining, drug-resistant forms of the disease, including MDR-TB, remain a growing concern, particularly in Asia and Africa (3). Addressing the social determinants of TB is essential to curbing its transmission.

Diagnostic Advances in Tuberculosis Early diagnosis is crucial for TB control. Traditional diagnostic methods, including smear microscopy and culture, have significant limitations in terms of sensitivity and speed (4). Molecular diagnostic tools such as GeneXpert MTB/RIF are revolutionizing TB diagnostics, offering rapid and accurate detection of both TB and drug resistance, as shown in Table 1. The introduction of whole-genome sequencing (WGS) further enhances the capacity to identify genetic mutations associated with drug resistance (5). These advances allow for earlier treatment initiation, improving outcomes, especially in drug-resistant cases.

Table 1: Common Diagnostic Methods for Tuberculosis

Diagnostic Method	Description	Sensitivity (%)	Specificity (%)	Time to Results
Sputum Smear Microscopy	Microscopic examination of stained sputum samples	30-70	90-95	Hours to Days
Culture on Solid Media	Growth of *Mycobacterium tuberculosis* on solid media	70-80	98-100	Weeks
Liquid Culture (MGIT)	Automated system for liquid culture	90-95	98-100	7-14 Days
GeneXpert MTB/RIF	Rapid molecular test for TB and rifampicin resistance	90-95	97-100	2 Hours
Whole Genome Sequencing (WGS)	Comprehensive genetic analysis of *Mycobacterium*	100	Variable	Days to Weeks

Treatment Advances in Tuberculosis

Drug-Sensitive TB: Optimizing Standard Treatment Regimens For drug-sensitive TB, the standard treatment regimen includes a six-month course of isoniazid, rifampicin, pyrazinamide, and ethambutol (6). This regimen is highly effective when adhered to properly, but poor patient adherence and side effects can lead to treatment failures. Recent studies have focused on optimizing treatment duration and drug combinations. One promising development is the use of rifapentine, a long-acting rifamycin, which has shown potential to reduce the treatment duration to four months in some cases, improving adherence without compromising efficacy (7).

Drug-Resistant TB: Breakthroughs in Treatment Options The management of MDR-TB and extensively drug-resistant TB (XDR-TB) has been challenging due to the length and toxicity of traditional regimens. However, new and improved treatment options are transforming outcomes for patients with drug-resistant TB, as outlined in Table 2.

Bedaquiline: Approved in 2012, bedaquiline has become a cornerstone in the treatment of MDR-TB. It works by inhibiting mycobacterial ATP synthase, a novel mechanism compared to traditional TB drugs (8). Clinical trials have demonstrated that bedaquiline, when used in combination with other TB drugs, significantly improves treatment success rates and reduces the duration of therapy (9).

Delamanid: Another breakthrough drug, delamanid, works by inhibiting mycolic acid synthesis, an essential component of the TB bacterial cell wall. It is particularly effective in combination with other drugs for treating MDR-TB and XDR-TB, reducing the duration of treatment to 9-12 months (10).

Pretomanid: More recently, pretomanid has been added to the treatment arsenal. When combined with bedaquiline and linezolid (the BPaL regimen), pretomanid has shown success in treating XDR-TB and complicated MDR-TB cases. This combination offers an all-oral, shorter-duration regimen that improves patient adherence and minimizes adverse effects (11). The BPaL regimen has been hailed as a breakthrough, with cure rates reaching up to 90% in clinical trials (12).

Shorter Regimens: The WHO now recommends shorter, all-oral regimens for MDR-TB, including a combination of bedaquiline, linezolid, clofazimine, and fluoroquinolones (13). These regimens, lasting between 9-12 months, represent a significant improvement over the previous 18–24-month treatments, leading to higher cure rates and fewer side effects.

Table 2: Comparison of Standard and New Treatment Regimens for Drug-Sensitive TB

Treatment Regimen	Duration	Components	Cure Rate (%)	Notes
Standard (Isoniazid + Rifampicin + Pyrazinamide + Ethambutol)	6 months	INH, RIF, PZA, EMB	90-95	Requires strict adherence

Rifapentine + Isoniazid	3-4 months	RPT, INH	88	Shorter duration, improved adherence
Shorter all-oral regimen for MDR-TB	9-12 months	BDQ, LZD, CFX, CLO	80-90	Fewer side effects

Control and Prevention Strategies

Controlling TB requires a combination of effective treatment and public health strategies. While the Bacille Calmette-Guérin (BCG) vaccine remains widely used, its efficacy is limited, particularly in preventing adult pulmonary TB (14). Research into more effective vaccines, such as the M72/AS01E, is ongoing and offers hope for improved TB prevention, as shown in Table 3 (15).

Public Health Interventions

Public health strategies such as active case finding, community-based treatment, and contact tracing have shown success in reducing TB transmission in high-burden settings. These interventions must be supported by strengthening healthcare systems and addressing social determinants, such as poverty and malnutrition, to achieve long-term success (16).

Table 3: Current and Future Vaccines for Tuberculosis

Vaccine Name	Type	Stage of Development	Efficacy (%)	Target Population
BCG	Live attenuated	Licensed	70-80	Infants
M72/AS01E	Protein subunit	Phase 2b clinical trial	50	Adults at high risk
H56	Protein subunit	Phase 1 clinical trial	TBD	High-risk populations
VPM1002	Live recombinant	Phase 2 clinical trial	TBD	Infants and adolescents

Methods

This review article was developed through a systematic approach to gather, analyze, and synthesize relevant literature on tuberculosis (TB). The methods employed are outlined as follows:

1. Literature Search: A comprehensive literature search was conducted using databases such as PubMed, Scopus, Web of Science, and Google Scholar. The search terms included "tuberculosis," "diagnosis," "treatment," "drug-resistant TB," "molecular diagnostics," and "public health strategies."
2. Selection Criteria: Articles were included based on predefined criteria: studies published in peer-reviewed journals between 2006 and 2023, focusing on advancements in TB diagnosis and treatment, including those addressing drug-sensitive and drug-resistant strains. Review articles, clinical trials, and meta-analyses were prioritized.
3. Data Extraction: Key information was extracted from selected articles, including study design, sample size, diagnostic methods, treatment regimens, outcomes, and public health strategies. Data was compiled in a systematic manner to facilitate comparison and synthesis.
4. Synthesis of Findings: The extracted data was analyzed qualitatively to identify trends, advancements, and gaps in the current literature. This synthesis informed the development of the review's sections, ensuring a comprehensive overview of recent developments in TB management.
5. Quality Assessment: The quality of included studies was assessed using established criteria, ensuring that only robust and relevant findings contributed to the review.

Discussion

While recent advances in TB treatment, particularly for drug-resistant forms, offer hope, challenges remain. The availability and affordability of newer drugs like bedaquiline and pretomanid must be ensured in low-resource settings. Furthermore, the development of shorter, more tolerable regimens continues to be a priority. Future research should focus on refining these regimens and expanding

access to effective diagnostics and treatment in underserved populations, as shown in Table 4.

Table 4: Global Tuberculosis Statistics (2022)

Region	Incidence (per 100,000)	Total Cases (estimated)	Mortality Rate (%)	MDR-TB Prevalence (%)
Africa	225	2.5 million	24.4	4.3
Asia	129	5.8 million	15.0	3.5
Eastern Europe	58	450,000	15.6	15.4
Western Pacific	49	1.8 million	8.0	2.7

CONCLUSION

TB continues to pose a threat to global health, particularly with the rise of drug-resistant strains. However, the recent advancements in diagnostic methods, treatment options, and public health strategies provide a pathway to significantly reduce TB incidence and mortality. Collaborative efforts between governments, healthcare providers, and communities are essential to ensure these advancements translate into improved health outcomes. Future research should continue to focus on innovative treatments and preventive measures to eradicate TB.

REFERENCES

[1] World Health Organization. Global Tuberculosis Report 2022. Geneva: World Health Organization; 2022.

[2] Lönnroth, K., & Raviglione, M. (2016). The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals. Transactions of the Royal Society of Tropical Medicine and Hygiene, 110(3), 148–150. https://doi.org/10.1093/trstmh/trv108

[3] Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., Theron, G., Van Helden, P., Niemann, S., Merker, M., Dowdy, D., Van Rie, A., Siu, G. K. H., Pasipanodya, J. G., Rodrigues, C., . . . Warren, R. M. (2017). The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. The Lancet Respiratory Medicine, 5(4), 291–360. https://doi.org/10.1016/s2213-2600(17)30079-6

[4] Mitnick, C. D., White, R. A., Lu, C., Rodriguez, C. A., Bayona, J., Becerra, M. C., Burgos, M., Centis, R., Cohen, T., Cox, H., D'Ambrosio, L., Danilovitz, M., Falzon, D., Gelmanova, I. Y., Gler, M. T., Grinsdale, J. A., Holtz, T. H., Keshavjee, S., Leimane, V., Menzies, D., … Collaborative Group for Analysis of Bacteriology Data in MDR-TB Treatment (2016). Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. The European respiratory journal, 48(4), 1160–1170. https://doi.org/10.1183/13993003.00462-2016

[5] Dlamini, M. T., Lessells, R., Iketleng, T., & de Oliveira, T. (2019). Whole genome sequencing for drug-resistant tuberculosis management in South Africa: What gaps would this address and what are the challenges to implementation?. Journal of clinical tuberculosis and other mycobacterial diseases, 16, 100115. https://doi.org/10.1016/j.jctube.2019.100115

[6] Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., Higashi, J. M., Ho, C. S., Hopewell, P. C., Keshavjee, S. A., Lienhardt, C., Menzies, R., Merrifield, C., Narita, M., O'Brien, R., Peloquin, C. A., … Vernon, A. (2016). Official American Thoracic

Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 63(7), e147–e195. https://doi.org/10.1093/cid/ciw376

[7] Rothstein D. M. (2016). Rifamycins, Alone and in Combination. Cold Spring Harbor perspectives in medicine, 6(7), a027011. https://doi.org/10.1101/cshperspect.a027011

[8] Diacon, A. H., Pym, A., Grobusch, M. P., De Los Rios, J. M., Gotuzzo, E., Vasilyeva, I., Leimane, V., Andries, K., Bakare, N., De Marez, T., Haxaire-Theeuwes, M., Lounis, N., Meyvisch, P., De Paepe, E., Van Heeswijk, R. P., & Dannemann, B. (2014). Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. New England Journal of Medicine, 371(8), 723–732. https://doi.org/10.1056/nejmoa1313865

[9] Pontali, E., Sotgiu, G., D'Ambrosio, L., Centis, R., & Migliori, G. B. (2016). Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. The European respiratory journal, 47(2), 394–402. https://doi.org/10.1183/13993003.01891-2015

[10] Skripconoka, V., Danilovits, M., Pehme, L., Tomson, T., Skenders, G., Kummik, T., Cirule, A., Leimane, V., Kurve, A., Levina, K., Geiter, L. J., Manissero, D., & Wells, C. D. (2013). Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. The European respiratory journal, 41(6), 1393–1400.

[11] Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E., Moreira, J., Timm, J., McHugh, T. D., Wills, G. H., Bateson, A., Hunt, R., Van Niekerk, C., Li, M., Olugbosi, M., Spigelman, M., & Nix-TB Trial Team (2020). Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. The New England journal of medicine, 382(10), 893–902. https://doi.org/10.1056/NEJMoa1901814

[12] Tiberi, S., Buchanan, R., Caminero, J. A., Centis, R., Arbex, M. A., Salazar, M., Potter, J., & Migliori, G. B. (2017). The challenge of the new tuberculosis drugs. Presse medicale (Paris, France: 1983), 46(2 Pt 2), e41–e51. https://doi.org/10.1016/j.lpm.2017.01.016

[13] WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539517/

[14] Trunz, B. B., Fine, P., & Dye, C. (2006). Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet (London, England), 367(9517), 1173–1180. https://doi.org/10.1016/S0140-6736(06)68507-3

[15] Van Der Meeren, O., Hatherill, M., Nduba, V., Wilkinson, R. J., Muyoyeta, M., Van Brakel, E., Ayles, H. M., Henostroza, G., Thienemann, F., Scriba, T. J., Diacon, A., Blatner, G. L., Demoitié, M. A., Tameris, M., Malahleha, M., Innes, J. C., Hellström, E., Martinson, N., Singh, T., Akite, E. J., … Tait, D. R. (2018). Phase 2b Controlled Trial of M72/AS01$_E$ Vaccine to Prevent Tuberculosis. The New England journal of medicine, 379(17), 1621–1634. https://doi.org/10.1056/NEJMoa1803484

[16] Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., Gilpin, C., Glaziou, P., Grzemska, M., Mirzayev, F., Nakatani, H., & Raviglione, M. (2015). WHO's new End TB Strategy. The Lancet, 385(9979), 1799–1801. https://doi.org/10.1016/s0140-6736(15)60570-0